<DOC>
	<DOCNO>NCT00021268</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness tocladesine treat patient recurrent progressive metastatic colorectal cancer .</brief_summary>
	<brief_title>Tocladesine Treating Patients With Recurrent Progressive Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose tocladesine patient recurrent progressive metastatic colorectal cancer . - Determine qualitative quantitative toxicity drug patient . - Assess therapeutic activity patient treat drug . OUTLINE : This dose-escalation , multicenter study . Patients receive tocladesine IV continuously day 1-5 8-12 . Treatment repeat every 21 day 10 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos tocladesine maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD determine , 14 additional patient treat dose level . PROJECTED ACCRUAL : A total 3-38 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>8-chloro-cyclic adenosine monophosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis metastatic carcinoma colon rectum Recurrent progressive fail prior fluorouracil irinotecan chemotherapy , sequentially combination , unless unable tolerate irinotecan Measurable disease PATIENT CHARACTERISTICS : Age : 18 75 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 5 time ULN PT/aPTT great 1.2 time ULN Renal : Creatinine great 1.5 mg/dL Creatinine clearance least 50 mL/min No impair renal function Cardiovascular : No impaired cardiac function Other : No active infection No malignancy within past 5 year except basal cell squamous cell skin cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy Surgery : Not specify Other : No concurrent anticancer drug No concurrent chronic nonsteroidal antiinflammatory agent No concurrent chronic therapeutic anticoagulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2002</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>